Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation

Takahiro Oto; Mikio Okazaki; Ken Takata; Moritoki Egi; Masaomi Yamane; Shinichi Toyooka; Yoshifumi Sano; Gregory I. Snell; Keiji Goto; Shinichiro Miyoshi

doi:10.1016/j.athoracsur.2009.09.081

Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation

Takahiro Oto, Mikio Okazaki, Ken Takata, Moritoki Egi, Masaomi Yamane, Shinichi Toyooka, Yoshifumi Sano, Gregory I. Snell, Keiji Goto, Shinichiro Miyoshi

Research output: Contribution to journal › Article › peer-review

16 Citations (Scopus)

Abstract

Hepatotoxicity, including cholestasis, is a rare but significant complication of treatment with calcineurin inhibitors. Timely life-saving therapy with revision of immunosuppression is mandatory. A 43-year-old woman with pulmonary hypertension was found to have severe cholestasis (serum bilirubin up to 35 mg/dL) after a living-donor lobar lung transplantation. Calcineurin-inhibitor cholestasis markedly improved after withdrawal of the calcineurin inhibitor, initiation of sirolimus, and interleukin-2 receptor blockade. Awareness of the diagnostic criteria of this rare posttransplant complication is important to initiate timely therapy.

Original language	English
Pages (from-to)	1664-1665
Number of pages	2
Journal	Annals of Thoracic Surgery
Volume	89
Issue number	5
DOIs	https://doi.org/10.1016/j.athoracsur.2009.09.081
Publication status	Published - May 2010

ASJC Scopus subject areas

Surgery
Pulmonary and Respiratory Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.athoracsur.2009.09.081

Cite this

@article{1230340795e34bdba0d1058e49ae9977,

title = "Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation",

abstract = "Hepatotoxicity, including cholestasis, is a rare but significant complication of treatment with calcineurin inhibitors. Timely life-saving therapy with revision of immunosuppression is mandatory. A 43-year-old woman with pulmonary hypertension was found to have severe cholestasis (serum bilirubin up to 35 mg/dL) after a living-donor lobar lung transplantation. Calcineurin-inhibitor cholestasis markedly improved after withdrawal of the calcineurin inhibitor, initiation of sirolimus, and interleukin-2 receptor blockade. Awareness of the diagnostic criteria of this rare posttransplant complication is important to initiate timely therapy.",

author = "Takahiro Oto and Mikio Okazaki and Ken Takata and Moritoki Egi and Masaomi Yamane and Shinichi Toyooka and Yoshifumi Sano and Snell, {Gregory I.} and Keiji Goto and Shinichiro Miyoshi",

year = "2010",

month = may,

doi = "10.1016/j.athoracsur.2009.09.081",

language = "English",

volume = "89",

pages = "1664--1665",

journal = "Annals of Thoracic Surgery",

issn = "0003-4975",

publisher = "Elsevier USA",

number = "5",

}

TY - JOUR

T1 - Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation

AU - Oto, Takahiro

AU - Okazaki, Mikio

AU - Takata, Ken

AU - Egi, Moritoki

AU - Yamane, Masaomi

AU - Toyooka, Shinichi

AU - Sano, Yoshifumi

AU - Snell, Gregory I.

AU - Goto, Keiji

AU - Miyoshi, Shinichiro

PY - 2010/5

Y1 - 2010/5

N2 - Hepatotoxicity, including cholestasis, is a rare but significant complication of treatment with calcineurin inhibitors. Timely life-saving therapy with revision of immunosuppression is mandatory. A 43-year-old woman with pulmonary hypertension was found to have severe cholestasis (serum bilirubin up to 35 mg/dL) after a living-donor lobar lung transplantation. Calcineurin-inhibitor cholestasis markedly improved after withdrawal of the calcineurin inhibitor, initiation of sirolimus, and interleukin-2 receptor blockade. Awareness of the diagnostic criteria of this rare posttransplant complication is important to initiate timely therapy.

AB - Hepatotoxicity, including cholestasis, is a rare but significant complication of treatment with calcineurin inhibitors. Timely life-saving therapy with revision of immunosuppression is mandatory. A 43-year-old woman with pulmonary hypertension was found to have severe cholestasis (serum bilirubin up to 35 mg/dL) after a living-donor lobar lung transplantation. Calcineurin-inhibitor cholestasis markedly improved after withdrawal of the calcineurin inhibitor, initiation of sirolimus, and interleukin-2 receptor blockade. Awareness of the diagnostic criteria of this rare posttransplant complication is important to initiate timely therapy.

UR - http://www.scopus.com/inward/record.url?scp=77953053479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953053479&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2009.09.081

DO - 10.1016/j.athoracsur.2009.09.081

M3 - Article

C2 - 20417810

AN - SCOPUS:77953053479

SN - 0003-4975

VL - 89

SP - 1664

EP - 1665

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

IS - 5

ER -

Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this